IP Verse

Natural Combination Hormone Replacement Formulations And Therapies - EP2861072

The patent EP2861072 was granted to Therapeuticsmd on Oct 18, 2023. The application was originally filed on Jun 18, 2013 under application number EP13806855A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2861072

THERAPEUTICSMD
Application Number
EP13806855A
Filing Date
Jun 18, 2013
Status
Granted And Under Opposition
Sep 15, 2023
Grant Date
Oct 18, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

RIECKJul 18, 2024FUCHS PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
ARISTO PHARMAJul 16, 2024GILLE HRABAL PARTNERSCHAFTSGESELLSCHAFT MBB PATENTANWALTEADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2009318558
INTERNATIONAL-SEARCH-REPORTUS2010136105
INTERNATIONAL-SEARCH-REPORTUS6294192
INTERNATIONAL-SEARCH-REPORTWO03077923
OPPOSITIONEP0955042
OPPOSITIONUS2011312928
OPPOSITIONUS4900734
OPPOSITIONWO2013078422
OPPOSITIONWO2013192251
OPPOSITIONWO9740823
SEARCHUS2003077297
SEARCHUS2011312928
SEARCHUS4900734

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Abitec, "Safety data sheet: Capmul® MCM NF", ABITEC, (20110724), pages 1 - 5, XP055906278-
OPPOSITION- Anonymous, "CAPMUL® MCM NF - Technical Data Sheet", ABITEC, (20140214), ABITEC, URL: https://www.stobec.com/DATA/PRODUIT/1605~v~data_8608.pdf, XP093195733-
OPPOSITION- Anonymous, "Gelucire ® 44/ 14 - Self-emulsifying exci pient for solubility and oral bioava ilabi lity enhancement ", GATTEFOSSE, (20190101), XP093196672-
OPPOSITION- Anonymous, "Medium Chain Triglycerides", Abitec; Captex, (20151201), XP093196679-
OPPOSITION- B. John Cannon, Et Al., "Emulsions, Microemulsions and Lipid-based Drug Delivery Systems for Drug Solubilization and Delivery - Part II: Oral Applications", Water Insoluble Drug Formulation Second Edition, (20080101), pages 227 - 254, XP055466108-
OPPOSITION- D18: US FDA label for Bijuva®-
OPPOSITION- D19: Estradiol valerate and Estradiol datasheets-
OPPOSITION- REICH G., "Formulation and physical properties of soft capsules, Chapter 11", REICH G., Podczeck Fridrun ; Jones Brian E., Pharmaceutical Capsules, GB , Pharmaceutical Press , (20040101), vol. 2nd ed., pages 201 - 212, ISBN 978-0-85369-568-4, XP008101385-
OPPOSITION- Hetal N. Prajapati; Damon M. Dalrymple; Abu T. M. Serajuddin, "A Comparative Evaluation of Mono-, Di- and Triglyceride of Medium Chain Fatty Acids by Lipid/Surfactant/Water Phase Diagram, Solubility Determination and Dispersion Testing for Application in Pharmaceutical Dosage Form Development", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20110823), vol. 29, no. 1, doi:10.1007/s11095-011-0541-3, ISSN 1573-904X, pages 285 - 305, XP019993288
OPPOSITION- Anonymous, "The 2012 Hormone Therapy Position Statement of The North American Menopause Society", Menopause: The Journal of The North American Menopause Society, Lippincott Williams & Wilkins, US, US , (20120301), vol. 19, no. 3, doi:10.1097/gme.0b013e31824b970a, ISSN 1072-3714, pages 257 - 271, XP093196682

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents